A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia

Vosaroxin is a first-in-class anticancer quinolone derivative that intercalates DNA and inhibits topoisomerase II. This study assessed the safety and tolerability of vosaroxin plus cytarabine in patients with relapsed/refractory acute myeloid leukemia. Escalating vosaroxin doses (10-minute infusion;...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Haematologica
Auteurs principaux: Lancet, Jeffrey E., Roboz, Gail J., Cripe, Larry D., Michelson, Glenn C., Fox, Judith A., Leavitt, Richard D., Chen, Tianling, Hawtin, Rachael, Craig, Adam R., Ravandi, Farhad, Maris, Michael B., Stuart, Robert K., Karp, Judith E.
Format: Artigo
Langue:Inglês
Publié: Ferrata Storti Foundation 2015
Sujets:
Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4803139/
https://ncbi.nlm.nih.gov/pubmed/25381131
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2014.114769
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires